- Home
- GHRS vs CDNA Comparison
GHRS vs CDNA Comparison
Compare GHRS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | CDNA |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 1.1B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GHRS | CDNA |
|---|---|---|
| Price | $21.65 | $20.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $41.38 | $28.00 |
| AVG Volume (30 Days) | 255.2K | ★ 733.8K |
| Earning Date | 05-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $409.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $10.67 | $10.96 |
| 52 Week High | $24.66 | $23.24 |
Technical Indicators
Market Signals| Indicator | GHRS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.68 | 47.72 |
| Support Level | $12.41 | $16.63 |
| Resistance Level | $22.88 | $21.20 |
| Average True Range (ATR) | 1.33 | 1.33 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 67.96 | 38.34 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.